{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:efdoralprin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:fiztasovimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ligufalimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vipalanebart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:efpegerglucagon [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:perenostobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:barzolvolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00173537: Not Applicable Interventional Unknown status Pulmonary Hypertension
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04631016: Phase 2 Interventional Completed Chronic Obstructive Pulmonary Disease (COPD)
(2020)
Source URL:
Class:
PROTEIN
